Last updated: April 19, 2026

Application No. 18/025,853

COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE

Non-Final OA

Filed

Mar 10, 2023

Examiner

HEASLEY, MEGHAN CHRISTINE

Art Unit

1626

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Genzyme Corporation

OA Round

1 (Non-Final)

Interview Optional

— +33.6% interview lift. This examiner has a relatively high allow rate; a written response may suffice.

Based on 109 resolved cases, 2023–2026

Examiner Intelligence

HEASLEY, MEGHAN CHRISTINE View full profile →

Grants 76% — above average

Career Allow Rate

83 granted / 109 resolved

+16.1% vs TC avg

Strong +34% interview lift

Without

With

+33.6%

Interview Lift

resolved cases with interview

Typical timeline

3y 1m

Avg Prosecution

35 currently pending

Career history

144

Total Applications

across all art units

Statute-Specific Performance

§101

1.8%

-38.2% vs TC avg

§103

33.3%

-6.7% vs TC avg

§102

18.4%

-21.6% vs TC avg

§112

27.2%

-12.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Prosecution Timeline

Mar 10, 2023

Application Filed

Jan 13, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/756,789

Patent 12600716

COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF

2y 5m to grant Granted Apr 14, 2026

18/386,267

Patent 12600715

SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS

2y 5m to grant Granted Apr 14, 2026

18/532,785

Patent 12599560

LIPIDS AND LIPID NANOPARTICLE FORMULATIONS

2y 5m to grant Granted Apr 14, 2026

17/271,829

Patent 12582637

NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF

2y 5m to grant Granted Mar 24, 2026

18/252,039

Patent 12577213

DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF

2y 5m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

76%

Grant Probability

99%

With Interview (+33.6%)

3y 1m

Median Time to Grant

Low

PTA Risk

Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE

Interview Optional

Examiner Intelligence

Statute-Specific Performance

Prosecution Timeline

Precedent Cases

Applications granted by this same examiner with similar technology

AI Strategy Recommendation

Prosecution Projections

Ready to respond to this office action?

Sign in with your work email